Medicus Pharma Ltd. (MDCX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The price action of Medicus Pharma Ltd. (MDCX) demonstrates an EV/EBITDA multiple of 0.00. Medicus Pharma Ltd. is creating an alternative to surgical interventions by developing microneedle patches for the precise administration of doxorubicin, which is currently undergoing the FDA approval process. Revenue is generated through the supply of basal cell carcinoma treatment technologies to specialized centers. The business's success is based on the effectiveness of new methods for overcoming the skin barrier in oncology therapy.

Medicus Pharma Limited - MDCX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for medicuspharma.com (MDCX)

- market price and analyst price targets:

Price Chart Medicus Pharma Limited|MDCX - Analyst Median Target

- market capitalization details:

Market Value Medicus Pharma Corp|MDCX - Enterprise Value

- book value of equity indicators:

Book Value per Share Medicus Pharma|MDCX - Book Valuation of Business|Market Value to Book Value Ratio medicuspharma.com|MDCX - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

MDCX - Net Income|Future Profit Medicus Pharma Ltd.|MDCX - P/E Multiple|Future Price to Earnings Medicus Pharma Ltd.|MDCX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Medicus Pharma Corp|MDCX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Medicus Pharma|MDCX - Earnings per one share for the last 12 months|Quarterly EPS earnings growth medicuspharma.com|MDCX - Earnings per share increase in current year|Earnings growth forecast for next year Medicus Pharma Ltd.

Initial company analysis:Medicus Pharma Limited MDCX

The integration of ESG environmental standards and plastic recycling in Medicus Pharma Ltd. (MDCX) packaging requires significant capital expenditures, which impact the debt load. Analyzing this EV/EBITDA chart, the investor assesses the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization, allowing for the determination of the asset's fair value inclusive of debt and the minimization of overpayment risk.

Competitor analysis for Medicus Pharma Ltd.

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Apogee Corp (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Tech|Enterprise Value to Operating Income Before Depreciation SLSN (Solesence Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Journey Medical (DERM)|Enterprise Value to EBITDA Ratio fortebiorx.com FBRX|EV/EBITDA Multiple EMPG (Empro Group)|Sol-Gel Technologies Ltd (SLGL) - Company Value to EBITDA|Revive Pro Care - EV/EBITDA Multiple|VRCA (Verrica Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|HOTH: EV/EBITDA Multiple|BFRI - Total Company Value to Operating Income Before Depreciation Ratio|VYNE (VYNE Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sonoma Pharma (SNOA)|Enterprise Value to EBITDA Ratio QNRX (Quoin Pharmaceuticals)|EV/EBITDA Multiple Azitra Corporation (AZTR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dermata Therapeutics DRMA|Total Company Value to Operating Income Before Depreciation Ratio elevaiskincare.com (ELAB)|RVNC: Enterprise Value to EBITDA Ratio